Your browser is no longer supported. Please, upgrade your browser.
EDSA Edesa Biotech, Inc. monthly Stock Chart
EDSA [NASD]
Edesa Biotech, Inc.
Index- P/E- EPS (ttm)-0.62 Insider Own5.90% Shs Outstand8.86M Perf Week5.40%
Market Cap48.64M Forward P/E- EPS next Y-1.38 Insider Trans1.02% Shs Float5.08M Perf Month-13.32%
Income-5.30M PEG- EPS next Q-0.21 Inst Own22.40% Short Float1.01% Perf Quarter-35.34%
Sales0.70M P/S69.49 EPS this Y94.80% Inst Trans6.99% Short Ratio0.23 Perf Half Y66.59%
Book/sh0.60 P/B8.78 EPS next Y-107.60% ROA-77.50% Target Price- Perf Year4.43%
Cash/sh- P/C- EPS next 5Y- ROE-97.50% 52W Range1.58 - 19.10 Perf YTD28.54%
Dividend- P/FCF- EPS past 5Y58.90% ROI- 52W High-72.41% Beta0.65
Dividend %- Quick Ratio- Sales past 5Y2.00% Gross Margin84.20% 52W Low233.54% ATR0.38
Employees10 Current Ratio6.30 Sales Q/Q21897.00% Oper. Margin- RSI (14)36.75 Volatility6.95% 6.77%
OptionableNo Debt/Eq0.00 EPS Q/Q33.50% Profit Margin- Rel Volume0.20 Prev Close5.30
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume227.48K Price5.27
Recom- SMA20-5.49% SMA50-21.00% SMA2007.68% Volume45,433 Change-0.57%
Nov-06-20 08:00AM  
Nov-03-20 07:25AM  
Oct-19-20 07:30AM  
Aug-31-20 05:00PM  
Aug-21-20 04:02PM  
05:55AM  
Aug-12-20 07:45AM  
Jul-30-20 07:45AM  
Jun-15-20 08:15AM  
May-27-20 07:20AM  
May-19-20 06:47AM  
May-15-20 08:00AM  
Apr-24-20 08:35AM  
Apr-20-20 09:00AM  
Apr-02-20 10:33AM  
Mar-12-20 07:30AM  
Feb-13-20 04:10PM  
Jan-06-20 09:21AM  
Dec-12-19 04:30PM  
Dec-03-19 07:30AM  
Nov-05-19 07:30AM  
Oct-21-19 07:30AM  
Aug-29-19 08:30AM  
Aug-14-19 04:05PM  
Jul-25-19 07:30AM  
Jun-20-19 12:12PM  
08:26AM  
07:30AM  
07:30AM  
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the development and advancement of treatments for dermatological and gastrointestinal indications. Its lead product candidate is EB01, a non-steroidal anti-inflammatory molecule to treat chronic allergic contact dermatitis. Edesa Biotech, Inc. has a collaborative research project with the National Research Council of Canada to develop novel immunotherapies for vitiligo, as well as other indications; and Light Chain Bioscience for the development and commercialization of two Phase 2-ready biologic drug candidates for various therapeutic, prophylactic, and diagnostic applications. The company was founded in 2015 and is headquartered in Markham, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Brooks Michael JPresidentMay 27Buy3.002,5007,4994,327May 29 09:20 AM
Nijhawan PardeepChief Executive OfficerMay 26Buy2.983,0008,9392,124,024May 28 12:19 PM
Nijhawan PardeepChief Executive OfficerMar 17Buy1.875,0009,3732,121,024Mar 19 10:34 AM
Sistilli CarloDirectorJan 08Buy4.112,43610,0122,436Jan 10 02:13 PM
van der Velden PeterDirectorJan 08Buy3.20140,625450,0001,833,066Jan 10 02:13 PM
JOHNSON LORIN KDirectorJan 08Buy4.118,52435,0348,524Jan 10 02:11 PM
Brooks Michael JPresidentJan 08Buy4.111,8277,5091,827Jan 10 02:09 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.